 NEW YORK, April 29, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced that data related to REL-1017, the companys lead product candidate, will be presented in six posters at the 2021 Society of Biological Psychiatry SOBP Annual Meeting, which is being held virtually between April 29 and May 1, 2021. Details of the presentations are below: DateTime: April 29, 2021, from 1:15 2:15 PM ET Poster Number: T142 Title: Esmethadone REL-1017 Antagonizes NMDA Receptors and Reduces Ca2 Entry in Presence of Quinolinic Acid and Gentamicin Session: Poster Session I DateTime: April 29, 2021, from 1:15 2:15 PM ET Poster Number: T143 Title: Esmethadone REL-1017 Reduces Glutamate-Induced Currents in NMDA Receptors with the GluN2D Subunit Session: Poster Session I DateTime: April 30, 2021, from 1:00 2:00 PM ET Poster Number: F136 Title: Esmethadone REL-1017 Compares with NMDA Receptor Antagonists in FLIPR Ca2 Assay Session: Poster Session II DateTime: April 30, 2021, from 1:00 2:00 PM ET Poster Number: F137 Title: Esmethadone REL-1017 Shows Similar Effects to Ketamine in Manual Patch Clamp Studies Session: Poster Session II DateTime: May 1, 2021, from 1:30 2:30 PM ET Poster Number: S138 Title: Esmethadone REL-1017 Restores NMDA Receptor 1 Subunit Expression in an In Vitro Model of Glutamatergic Excitotoxicity Session: Poster Session III DateTime: May 1, 2021, from 1:30 2:30 PM ET Poster Number: S143 Title: Esmethadone REL-1017 Reduces Glutamate-Induced Currents in NMDA Receptors in a Concentration Dependent Manner Session: Poster Session III About REL-1017 REL-1017, a novel NMDA receptor NMDAR channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is entering late-stage studies as an adjunctive treatment for MDD in adults. 